H.C. Wainwright Reiterates Buy On OncoSec Following YTD Results
In a research note issued this morning, H.C. Wainwright analyst Reni Benjamin reiterated coverage with a “Buy” rating on OncoSec Medical Inc. (ONCS), and a price target of $2.00 a share based on a comparables analysis of similarly staged biotechnology companies with platform technologies.
“With multiple upcoming presentations, the potential for a partnership, and a strong cash position of approximately $39 MM (pro forma), we believe OncoSec represents an undervalued player with significant upside for the long-term investor”, wrote Benjamin.
According to TipRanks, which measures analysts and bloggers success rate based on how their calls perform, analyst Reni Benjamin currently has a one-year average return of 5.9% and a 53% success rate. He is ranked #1358 out of 3114 analysts.